75010 Federal Register / Vol. 88, No. 210 / Wednesday, November 1, 2023 / Notices 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Drug 

Discovery and Molecular Pharmacology. 

Date: November 15, 2023. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jeffrey Smiley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6194, 

MSC 7804, Bethesda, MD 20892, (301) 272– 

4596, smileyja@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflicts: Auditory, Visual and Cognitive 

Neuroscience. 

Date: November 30, 2023. 

Time: 11:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Alena Valeryevna 

Savonenko, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 1009J, Bethesda, MD 20892 (301) 594– 

3444, savonenkoa2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; AREA/ 

REAP: Respiratory, Cardiac and Circulatory 

Sciences. 

Date: November 30, 2023. 

Time: 1:00 p.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kirk E Dineley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institute of 

Health, 6701 Rockledge Drive, Room 806E, 

Bethesda, MD 20892, (301) 867–5309, 

dineleyke@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Skeletal Muscle and Exercise 

Physiology/Musculoskeletal Rehabilitation 

Sciences. 

Date: December 5, 2023. 

Time: 9:30 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Aftab A Ansari, Ph.D., 

Scientific Review, Officer Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4108, 

MSC 7814, Bethesda, MD 20892, (301) 237– 

9931, ansaria@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Musculoskeletal, Dental and Oral 

Sciences. 

Date: December 6, 2023. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Chee Lim, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 4128, Bethesda, MD 20892, 

(301) 435–1850, limc4@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–21– 

120: Fogarty Global Infectious Disease 

Research Training Program. 

Date: December 8, 2023. 

Time: 10:00 a.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Dayadevi Jirage, Ph.D., 

Scientific Review, Officer Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4422, 

Bethesda, MD 20892, (301) 867–5309, 

jiragedb@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 26, 2023. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2023–24116 Filed 10–31–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Fiscal Year (FY) 2024 Notice of 

Supplemental Funding Opportunity 

AGENCY: Substance Abuse and Mental 

Health Services Administration, 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of intent to award 

supplemental funding. 

SUMMARY: This notice is to inform the 

public that the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) is supporting a supplement 

in scope of the original award to the 

Community-Based, Advocacy-Focused, 

Data-Driven, Coalition-Building 

Association (CADCA) recipient funded 

in FY 2019 under the National AntiDrug Coalitions Training and Workforce 

Development Grant Program (Short 

Title: Coalitions Training Grant), Notice 

of Funding Opportunity (NOFO) SP–19– 

002. The recipient may receive up to 

$562,500. The supplemental funding 

will extend the project period by 10- 

months until September 29, 2024 and 

will: leverage existing resources and 

conference support to expand 

SAMHSA’s scope and capacity; and 

provide training and technical 

assistance to state and community 

prevention leaders, including members 

of anti-drug community coalitions from 

around the country who are committed 

to addressing the evolving needs of the 

behavioral health field. The training and 

workforce development activities 

supported through this grant include 

SAMHSA’s Prevention Day and 

SAMHSA’s participation in the annual 

National Leadership Forum and annual 

Mid-Year Training Institute of CADCA. 

FOR FURTHER INFORMATION CONTACT: 

David Lamont Wilson, Public Health 

Analyst, Substance Abuse and Mental 

Health Services Administration, 5600 

Fishers Lane, Rockville, MD 20857, 

telephone 240–276–2588; email: 

david.wilson@samhsa.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Funding Opportunity Title: FY 2019 

National Anti-Drug Coalitions Training 

and Workforce Development Grant 

Program (Short Title: Coalitions 

Training Grant), Notice of Funding 

Opportunity SP–19–002. 

Assistance Listing Number: 93.243. 

Authority: The Coalitions Training 

Grant is authorized under sections 509, 

516 and 520A of the Public Health 

Service Act, as amended. 

Justification: Eligibility for this 

supplemental funding is limited to 

CADCA, which was funded in FY 2019 

under the National Anti-Drug Coalitions 

Training and Workforce Development 

Grant Program (Short Title: Coalitions 

Training Grant). CADCA is the only 

national organization that provides 

training and technical assistance 

annually through a national leadership 

conference for thousands of members of 

community coalitions dedicated to 

preventing substance use. CADCA is 

currently the sole organization that 

plays a major role in helping to 

strengthen and develop the nation’s 

prevention infrastructure of anti-drug 

coalitions in support of ongoing 

activities funded by SAMHSA’s priority 

prevention grant programs. It is the only 

identified organization that currently 

meets this experience level and national 

reach to over 5,000 identified anti-drug 

coalitions across the country. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 210 / Wednesday, November 1, 2023 / Notices 75011 

This is not a formal request for 

application. Assistance will only be 

provided to Coalitions Training Grant 

(CADCA) funded in FY 2019 based on 

the receipt of a satisfactory application 

and associated budget that is approved 

by a review group. 

Dated: October 27, 2023. 

Ann Ferrero, 

Public Health Analyst. 

[FR Doc. 2023–24125 Filed 10–31–23; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine and Oral 

Fluid Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITFs) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs using Urine or Oral Fluid 

(Mandatory Guidelines). 

FOR FURTHER INFORMATION CONTACT: 

Anastasia Flanagan, Division of 

Workplace Programs, SAMHSA/CSAP, 

5600 Fishers Lane, Room 16N06B, 

Rockville, Maryland 20857; 240–276– 

2600 (voice); Anastasia.Flanagan@

samhsa.hhs.gov (email). 

SUPPLEMENTARY INFORMATION: In 

accordance with Section 9.19 of the 

Mandatory Guidelines, a notice listing 

all currently HHS-certified laboratories 

and IITFs is published in the Federal 

Register during the first week of each 

month. If any laboratory or IITF 

certification is suspended or revoked, 

the laboratory or IITF will be omitted 

from subsequent lists until such time as 

it is restored to full certification under 

the Mandatory Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at https://www.samhsa.gov/ 

workplace/resources/drug-testing/ 

certified-lab-list. 

The Department of Health and Human 

Services (HHS) notifies federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITFs) 

currently certified to meet the standards 

of the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines) using Urine and 

of the laboratories currently certified to 

meet the standards of the Mandatory 

Guidelines using Oral Fluid. 

The Mandatory Guidelines using 

Urine were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines using Oral 

Fluid were first published in the 

Federal Register on October 25, 2019 

(84 FR 57554) with an effective date of 

January 1, 2020. 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71 and allowed urine 

drug testing only. The Mandatory 

Guidelines using Urine have since been 

revised, and new Mandatory Guidelines 

allowing for oral fluid drug testing have 

been published. The Mandatory 

Guidelines require strict standards that 

laboratories and IITFs must meet in 

order to conduct drug and specimen 

validity tests on specimens for federal 

agencies. HHS does not allow IITFs to 

conduct oral fluid testing. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines using Urine and/ 

or Oral Fluid. An HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that the test facility has met minimum 

standards. HHS does not allow IITFs to 

conduct oral fluid testing. 

HHS-Certified Laboratories Approved 

To Conduct Oral Fluid Drug Testing 

In accordance with the Mandatory 

Guidelines using Oral Fluid dated 

October 25, 2019 (84 FR 57554), the 

following HHS-certified laboratories 

meet the minimum standards to conduct 

drug and specimen validity tests on oral 

fluid specimens: At this time, there are 

no laboratories certified to conduct drug 

and specimen validity tests on oral fluid 

specimens. 

HHS-Certified Instrumented Initial 

Testing Facilities Approved To Conduct 

Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified IITFs meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

Dynacare, 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190 (Formerly: GammaDynacare Medical Laboratories) 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified laboratories meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

Desert Tox, LLC, 5425 E Bell Rd., Suite 

125, Scottsdale, AZ 85254, 602–457– 

5411/623–748–5045 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

Dynacare,* 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630, (Formerly: GammaDynacare Medical Laboratories) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609 

Laboratory Corporation of America 

Holdings, 7207 N Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 


ddrumheller on DSK120RN23PROD with NOTICES1